Invivyd, Inc.

Now, roughly a month and a half later, we are pleased to share that we have finished dosing all 30 participants in the trial. We remain on track for initial data readouts from that phase one trial in the second quarter with additional clinical readouts from the BYD222 program anticipated in 2023. We also recently announced that the US FDA has cleared our investigational new drug, IND, application for BYD222 an important step in our efforts to rapidly develop a therapeutic to protect the millions of immunocompromised people in the U.S. who are still under threat from COVID-19. Before I hand the call over to Pete to provide an overview of our VYD 222 program and our regulatory strategy, I will provide a brief overview of the patient population we are focused on and cover recent developments in the field that speak to the strong unmet need for new therapeutics for COVID-19. As you are aware, we are primarily focused on COVID-19 as it continues to remain a serious problem and a significant unmet medical need, particularly for immunocompromised people who remain vulnerable to the virus. People with dysfunctional or suppressed immune systems may not be able to mount an adequate response to vaccination and generate protective immunity. Therefore, immunocompromised people, which are estimated to number between 8 and 18 million people in the U.S. And 14 million people in the EU require a different approach to COVID-19 prevention that does not rely on a healthy and functioning immune system. This population includes, for example, people who take immunosuppressive drugs, including organ transplant recipients, and people with autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, or inflammatory bowel disease. This population also includes patients with hematological cancers that affect the immune system, like leukemia or lymphoma, as well as patients with forms of cancer that require treatments that weaken the immune system, such as chemotherapy. Immunocompromised people are at increased risk for severe COVID-19 outcomes, such as hospitalization and death, and are in urgent need of new therapeutic options. As SARS-CoV-2 has continued to circulate and mutate what clinicians have to offer these individuals in the global medicine cabinet has become extremely limited at present. For instance, there is increasing real-world evidence that suggests the bivalent mRNA boosters offer marginal protection against symptomatic disease caused by emerging variants of concern, even in people with normal immune systems. Now more than ever, immunocompromised people need the rapid protection provided by monoclonal antibodies. With the previously authorized anti-SARS-CoV-2 MABs losing activity against variants of concern and being removed from the market in the U.S., there remains a significant unmet need. With COVID-19 still threatening millions of people, we are pleased to see that COVID-19 is still a priority for the U.S. government. The recently announced Project NextGen and $5 billion of associated funding is evidence of the government's continued commitment to supporting the advancement of vaccines. and therapeutics that provide more durable protection and address future variants with new monoclonal antibodies identified as one of three priorities for the initiative. We are encouraged by the government's recognition that there remains a need to advance improved tools that provide better, broader, and more long-lasting protection. And we agree that multiple approaches beyond vaccines are needed to address the prevention and treatment of COVID-19. Filling this gap in the product landscape represents a significant market opportunity for InVivid. Consider that EvuShield captured $2.2 billion in total revenue in 2022 with strong growth prior to its removal from the market when it lost activity against emerging variants of concern. Additionally, the first quarter of 2023 in the biopharmaceutical industry has featured stronger than anticipated utilization of vaccines and drugs which, while counter to some who think COVID-19 is over, aligns with the vast unmet need that still exists. We believe that among all of the choices a vulnerable person and their healthcare professional can make relative to COVID-19, reducing the probability of having symptomatic COVID-19 that is not getting sick remains the strategy that is likely to lead to the lowest overall burden of disease and lowest negative health outcomes. While vaccines have done incredible work to keep us alive, there remains substantial work to keep vulnerable populations well. Monoclonal antibodies are well-suited to meet this gap by augmenting the human immune system and helping to protect vulnerable populations from COVID-19. While COVID-19 is transitioning into an ongoing endemic disease, it remains a massive disease category. Immunocompromised people who will continue to be at high risk could benefit significantly from monoclonal antibodies. Given the enduring need for these patients and the unique value proposition for MABS, we believe this market has the potential to become a high-growth, multibillion-dollar opportunity in the space for many years to come. Among the companies developing antibody-based therapeutics, we believe we are positioned to have a significant impact for vulnerable populations because of our differentiated approach, an approach that is grounded in a commitment to serial innovation and is designed to anticipate and quickly respond to viral evolution. Our approach to perpetual innovation has two key pillars. The first pillar is a cutting-edge viral and epidemiological surveillance. With these capabilities, we aim to predictively model and target future SARS-CoV-2 variants. The second pillar is our discovery engine, which includes industry-leading B-cell mining and antibody engineering capabilities through our internal expertise and collaborations, such as our partnership with Atomab. We leverage B-cell mining to isolate broadly neutralizing antibodies but we do not rely alone on the repertoire of antibodies naturally produced by humans in response to viral exposure. We take our work one step further by continually leveraging our antibody engineering capabilities to improve the potency, breadth, biophysical properties, and developability of the antibody candidates we discover through B-cell mining. With our discovery engine, we have generated multiple monoclonal antibody candidates for COVID-19, The first candidate from our engine, adentrevumab, we advanced from IND to pivotal clinical trial data in 16 months. Our second candidate, VYD222, is in clinical development now. VYD222 is unique because it is engineered from our previous candidate, adentrevumab, which demonstrated clinically meaningful results in global phase three clinical trials and has a robust safety data package. As Pete will discuss shortly, We aim to leverage insights from our experience with adentrevumab, including our recently published landmark research on monoclonal antibody correlates of protection to move much faster with the development of VYD222. Beyond VYD222, we have multiple anti-SARS-CoV-2 monoclonal antibodies in discovery and recently nominated an additional monoclonal antibody candidate for further preclinical characterization. This robust discovery pipeline reflects our strategy to predict and respond to variants before they become variants of concern and continuously discover and engineer new antibody candidates that can be leveraged to keep pace with viral evolution. I am proud of the tremendous progress we have made to advance our work in the recent months, and I look forward to continuing to drive our mission forward with the urgency and speed that these vulnerable populations deserve. I will now pass the call to Pete Schmidt, Chief Medical Officer, who will provide an update on our BYD 222 clinical program.

Thanks, Dave. As Dave mentioned, we are pleased to report that we have completed dosing all 30 participants in our Phase 1 clinical trial of BYD222. BYD222 is a broadly neutralizing monoclonal antibody candidate in development for the prevention of COVID-19 in vulnerable populations, such as immune-compromised people. BYD222 has demonstrated in vitro neutralizing activity against variants of concern, including Omicron sublineages up to and through XBB1.5. We continue to actively monitor emerging variants of concern and VYD222's in vitro neutralizing activity against these variants. VYD222 was engineered from adenotrevumab, our first investigational monoclonal antibody, which demonstrated clinically meaningful results in global phase three clinical trials and has a robust safety data package. Our precision engineering resulted in only eight amino acids that differ in the variable region of VYD222 compared to adentrevumab. This is our first example of reengineering one of our monoclonal antibody candidates to adapt to a viral shift. The ongoing VYD222 Phase I clinical trial is a randomized, blinded, placebo-controlled dose-ranging trial to evaluate the safety, pharmacokinetics, tolerability, and Serum Virus Neutralizing Activity, or SVNA, of BYD222 in healthy adult volunteers. The trial will evaluate three different doses, each administered as a single IV push. All doses are designed to provide durability in the face of viral evolution and flexibility at the time of regulatory submission. We are on track for initial readouts from the Phase I clinical trial in the second quarter. including initial insights into BYD222's serum virus neutralizing activity, which may provide an early look at anticipated clinical efficacy. Based on research we and our collaborators published in March 2023 in the peer-reviewed journal Science Translational Medicine, which relied heavily on data from our adentrovimab clinical trial, we believe that serum virus neutralizing activity is the optimal biomarker for predicting clinical efficacy and potentially accelerating the clinical development path for VYD222 when combined with associated pharmacokinetic safety data pending input from regulators. Our recently published paper establishes a quantitative relationship that defines a correlative protection for monoclonal antibodies, demonstrating protection from symptomatic infection even at relatively modest antibody titers. which speaks to the potential to have an extended period of time before needing to redose MAP therapies with extended half-lives. Additionally, the research indicates that antibodies, whether polyclonal or monoclonal, are mechanistic for protection against symptomatic disease. This groundbreaking work suggests that clinical efficacy of monoclonal antibodies against the SARS-CoV-2 spike protein is a predictable phenomenon that can be modeled. We see this publication as transformational towards accelerating the clinical development of monoclonal antibodies for the prevention of symptomatic COVID-19. On the regulatory front, we continue to be encouraged by the evolving regulatory landscape following the joint FDA EMA workshop in December of 2022, where alternative surrogate marker-based strategies for development of novel monoclonal antibody therapies for COVID-19 were discussed including a presentation by InVivid about the potential use of SVNA titers as a surrogate marker for protection against symptomatic COVID-19. Since that meeting, we have seen other companies in the COVID-19 MAP space refer to rapid development plans and the use of SVNA titers as surrogate endpoints in their clinical trials, which may suggest that the FDA and other major regulatory bodies have agreed in principle to such a trial design for next-generation MAP candidates. We intend to work closely with global regulators to ensure our clinical trials are designed to provide the data they require as they establish regulatory frameworks that reflect the pace of SARS-CoV-2 viral evolution. We have had constructive interactions with the FDA and EMA regarding our VYD222 development program and pending feedback from regulators. We plan to share an update once the design of our pivotal VYD222 clinical trial is finalized. Like we did with adentrevumab, our intention is to initiate the pivotal trial of BYD222 as quickly as possible on the heels of early positive data from our Phase 1 trial, including SVNA titers. To help ensure that we are well-positioned to support rapid recruitment into our planned Phase 3 trial, we have established a database of recruitment-ready, immunocompromised individuals for potential enrollment into the pivotal clinical trial. As the regulatory landscape evolves, one thing that remains the same is our belief that emergency use authorizations, or EUAs, continue to be an attractive pathway for authorization in the U.S., continuing past the end of the state of emergency around the COVID-19 pandemic. The FDA has confirmed that existing EUAs for vaccines, tests, and treatments will not be affected. and has further confirmed that it may continue to issue EUAs for new products that meet the required criteria. In fact, just last month a host-directed monoclonal antibody received emergency use authorization for the treatment of COVID-19 in hospitalized adults receiving mechanical ventilation or artificial life support. As we look ahead, we look forward to constructing, in partnership with global regulators, a future paradigm where viral-directed monoclonal antibodies have a standard rapid development pathway that is similar to the platform-based approach used for the periodic modification and approval of flu and SARS-CoV-2 vaccines. We are optimistic about our path forward from here and our ability to address the significant need for novel therapeutic approaches for the prevention of COVID-19, particularly for immune-compromised individuals. With that, I will turn the call over to Fred Driscoll, InVivid's Interim Chief Financial Officer, who will discuss our financials.

Thanks, Pete, and good afternoon, everyone. With respect to operating expenses, R&D expenses, including in-process R&D, were $28 million for the first quarter of 2023, compared to $92 million for the comparable period of 2022. This decrease is attributable to lower contract manufacturing costs driven by adentrevumab commercial manufacturing in 2022 with no comparable commercial manufacturing costs in 2023 and lower clinical trial costs due to the wind down of adentrevumab clinical trials. Our SG&A expenses were $11 million for the first quarter of 2023 compared to $8.7 million for the comparable period of 2022. This increase is attributable to lower stock-based compensation expense in 2022, partially offset by reduced consulting costs, professional fees, and public company costs in 2023. The net loss for the first quarter of 2023 was $35.3 million compared to $100.7 million for the comparable period in 2022. Basic and diluted net loss per share was $0.32 for the first quarter of 2023, compared to 93 cents for the comparable period in 2022. We exited the first quarter well capitalized with cash, cash equivalents, and marketable securities of $333 million. Based on our current operating plans, we expect our cash will enable the company to fund its operating expenses, excluding any potential revenue associated with VYD 222 into the second half of 2024. With that, operator, please open the call for questions.

If you'd like to ask a question at this time, please press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again. Please stand by while we compile the Q&A roster. Our first question comes from the line of Evan Wang with Joggenheim Securities.

Hi, guys. Congrats on the progress in completing enrollment. Just wondering, you know, in terms of recent interactions with regulatory agencies, how is that progressing? Have you proposed a phase three design? And I guess, how quickly can you approach them with phase one data? And I know you highlighted some aspects of potential phase three preparation that's currently ongoing, but how quickly could you move into phase three once a design is finalized? Thanks.

Yeah, thanks, Evan. Great to hear from you. Yeah, we're really excited about the quarter and the news that we have, you know, finished dosing all of the phase one cohort participants. A little bit more, right, so as a part of the IND, we submitted our design for the phase three pivotal study. So we're certainly excited about that and waiting for that. As I've mentioned previously, we've done a considerable amount of work to be ready and prepared for that clinical trial. As Pete mentioned in the call, we've even got this database of immunocompromised individuals that we're looking to utilize for that potential trial and to be able to enroll rapidly instead of sort of waiting and then starting from ground zero at that point in time. So that plus the clinical trial material all being made, all of the different elements in place, CROs lined up, et cetera, is a part of our underlying approach, which is to do this as quickly as possible. Seeing the need that still remains in vulnerable populations and the EUA pathway that continues to be open. And so that's all supportive of our desire to do this as quickly as possible and to be smart about these different preparations and be at the ready so that we really, once everything is completed and all the I's are dotted and T's are crossed, we can start. Pete, anything more from your side on the clinical preparation?

Yeah, I think completing dosing is a big milestone here because, of course, we will have to provide some data from the phase one to initiate the phase three, but we have no concerns about that happening quickly as well, as Dave said. And I had one follow-up.

I guess, how quickly will you be able to decide on a dose? Will this initial read into a queue, you know, give confidence in a go-forward pivotal dose? And how are you thinking about dosing for the phase three? Thanks.

Yeah, it's a great question. You know, we have two decision points on dosing. The answer to the first part is yes, we'll be able to decide on clinical dose from the early read from phase one that you'll see later this quarter. But there's also the concept of having dose flexibility at the time of submission. So that's why we studied this dose range, because as we know, the virus is evolving. the potency of the antibodies against the virus changes over time. And so we may be able to go with a lower dose at the time of submission than we decide in the pivotal trial. So we're kind of leaving the door open for multiple discussions there.

I think the only other thing I would add there that's really exciting about this initial read that we're talking about for the phase one is the SBNA data, which gives us a view based on the paper that we published to get an early readout where we would fall on that curve, which, as you know, would give us this correlative protection and these titer levels related to predicted efficacy of what they would be. And so, that will also greatly influence us, as well as looking at whatever new variants of concern are circulating throughout this period of time, we can apply those back into the model. and make some determinations and assessment of which is the most appropriate dose.

Thanks. We'll go back to you.

Our next question comes from the line of Patrick Trucchio with HC Wainwright.

Thanks. Good afternoon. Just a first question, a follow-up on the phase one data for VYD222. What serum virus neutralizing activity are you looking for in this initial data readout, and is there comparable data from earlier programs that would be good for us to look to, or is this, or, you know, would that earlier data be less relevant given the new variants and its new antibody?

Yeah, that's a great question. We anticipate the data will be against contemporary variants of concern, so looking back at previous variants or previous programs is probably not as valuable.

And just assuming that, you know, the phase three program kind of progresses as you would expect, I'm wondering if you can clarify for us the use of the emergency use authorization. Specifically, what would that submission process look like, you know, from the time of submission to a potential authorization, and if or when a BLA would be needed to ensure continued access

So the first part, right, so we continue to see timelines. We don't have information on exactly when other companies have filed EUAs, but certainly we've seen that that review period from the FDA doesn't fall under any specific clock, but that it is done in the past quite quickly. That's a part of being in the emergency use piece. So unlike the PDUFA dates and BLA timelines, which have a a very set clock. The, of course, good news, bad news about the EUA is that doesn't exist. And so we've seen it in months in the past. And certainly the idea is to be in continued conversations with regulatory authorities and providing them data along the way. And so they would have an understanding of what's coming in that package. I don't know, Pete, any other insights? I mean, there's certainly no know hard and fast pieces from them but with no antibodies on the market it certainly is not lost on on them or others the need for products like this and so that to us is certainly indicative of of why there would be a a quick review yeah I completely agree with Dave and and in terms of the BLA you know as the

criteria are currently written, you need to intend as a sponsor to continue to develop towards BLA. And our trials are designed, as you know, we have a long-term safety follow-up. Our trials are designed to potentially support a BLA as well.

Yeah, that's helpful. And then just one last one, if I may. What additional data, you know, appreciate the earlier comments about the openness of regulators on the approach with the surrogate endpoints, you know, but what additional data might they ask for, might the FDA or MA ask for, or what would they want to see maybe from trials that are already running to give further confidence in this surrogate endpoint approach for approving new antibodies in this COVID-19 setting?

Yeah, that's another good question. So there will always be this clinical endpoint portion of all of our studies. And the difference here is that it's not the primary endpoint anymore. But I do anticipate that we and others will continue to generate secondary endpoint supportive clinical data to confirm our primary endpoint surrogate markers. Yep. Terrific.

Thank you so much.

Thanks Patrick. Thank you.

Our next question comes from Michael Yee with Jefferies.

Hi, good afternoon. Thanks for taking our question. This is Jenna on for Mike. We wanted to follow up on the SCNA biomarker. And could you talk about what are your expectations on the biomarker? What level of reduction would you want to see for a different doses? Thank you.

Yeah, so what we've talked about in the past is really right from a target product profile, and our goal is to provide at least six months of protection. Now, these are highly vulnerable groups who are currently receiving infusions and are in a variety of outpatient and inpatient care. And so with what I said earlier as well, I mean, bivalent vaccines in terms of emerging data are showing limited protective properties against symptomatic disease, and that's in folks who have fully functioning immune systems. In these vulnerable populations, they're really looking for anything that can help them with prevention, and we speak with the patient populations frequently. And so what we really see here is getting a look at where we would be providing, and you can make some trade-offs between dose in terms of higher or lower and predicted duration of protection. And so those are the types of things that we're looking at. And then again, in the publication, we've specifically linked and shown that this correlate between these SPNA titers and efficacy from previous clinical studies is what has made that curve. And so you can see where you are on that curve and you know that's really what we're comparing those against and looking to provide again very usable products to people who currently have none got it thanks so much showing no further questions in queue at this time

I'd like to turn the call back to Dave Herring for closing remarks.

Thank you all for joining the call today. We are entering a transformational period that we believe has the potential to establish near-term and long-term success and value creation by realizing the potential of our strategy and technology. We thank you for your continued support and interest in InVivid, and we look forward to catching up with any of you individually over the coming days. Thank you so much.

This concludes today's conference call. Thank you for participating. You may now disconnect.